Evidence map›Paper›PMID 41315323›Full record

Trial reportScientific reports2025

Circulating tumor cells as prognostic biomarkers in advanced gastric cancer treated with CDC25B phosphatase inhibitors.

Francisco Cezar Aquino de Moraes, Danielle Queiroz Calcagno, Paulo Pimentel de Assumpção, Rommel Mario Rodríguez Burbano

Abstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Francisco Cezar Aquino de MoraesOncology Research Center, University Hospital João de Barros de Barreto, Federal University of Pará, Belém, Pará, 66073-000, Brazil. francisco.cezar2205@gmail.com.ORCID http://orcid.org/0000-0003-0623-8135
Danielle Queiroz CalcagnoOncology Research Center, University Hospital João de Barros de Barreto, Federal University of Pará, Belém, Pará, 66073-000, Brazil.
Paulo Pimentel de AssumpçãoOncology Research Center, University Hospital João de Barros de Barreto, Federal University of Pará, Belém, Pará, 66073-000, Brazil.
Rommel Mario Rodríguez BurbanoOncology Research Center, University Hospital João de Barros de Barreto, Federal University of Pará, Belém, Pará, 66073-000, Brazil.ORCID http://orcid.org/0000-0002-4872-234X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Targeted therapies, such as the CDC25B inhibitor menadione, have shown promise in treating gastric cancer (GC). Circulating tumor cells (CTCs) are emerging as a tool for monitoring treatment efficacy. This study aims to assess the impact of CTC counts on treatment outcomes and the efficacy of menadione in GC. This analysis of a phase II randomized trial included patients with gastric adenocarcinoma treated with Menadione plus XELOX or XELOX alone. Kaplan-Meier curves were used to analyze overall survival (OS) and progression-free survival (PFS), comparing CTC responders (CTC resp) and non-responders (No CTC resp). Hazard ratios (HR) and 95% confidence intervals (CI) were calculated, and p-values < 0.05 were considered significant. Of the 107 patients, 54 received Menadione + XELOX and 53 received XELOX alone. In the Menadione group, CTC responders had better OS, with HRs of 1.65 at 3 months, 7.47 at 6 months, and 1.90 at 15 months (p < 0.001). PFS analysis showed a higher risk of progression in No-CTC responders, with HRs of 2.28 at 3 months and 10.5 at 15 months (p < 0.001). Patients without CTC response had worse OS and PFS in both treatment groups, suggesting that CTC response could be a valuable predictor of clinical outcomes, warranting more intensive monitoring and tailored therapies for specific subgroups.

Indexed as

AdenocarcinomaAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, Tumorcdc25 PhosphatasesNeoplastic Cells, CirculatingStomach NeoplasmsAdultAgedCapecitabineFemaleHumansMaleMiddle AgedOxaloacetatesPrognosisProgression-Free SurvivalBiomarkers, TumorCapecitabineCDC25B protein, humancdc25 PhosphatasesOxaloacetatesVitamin K 3Circulating tumor cellsGastric cancerMenadione

Identifiers

PMID41315323
PMCPMC12663304

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.